Catalyst
Slingshot members are tracking this event:
GlycoMimetics (GLYC) Announces Dosing of First Patient in Phase I Trial of GMI-1271 in Multiple Myeloma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GLYC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Dosing Of First Patient, Phase I Trial, Gmi-1271, Multiple Myeloma
